Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2002 Aug 3;325(7358):243.
doi: 10.1136/bmj.325.7358.243.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Carol E Koro  1 , Donald O Fedder, Gilbert J L'Italien, Sheila S Weiss, Laurence S Magder, Julie Kreyenbuhl, Dennis A Revicki, Robert W Buchanan
Affiliations
Comparative Study

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Carol E Koro et al. BMJ. .

Abstract

Objective: To quantify the association between olanzapine and diabetes.

Design: Population based nested case-control study.

Setting: United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000.

Participants: 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls.

Main outcome measures: Diagnosis and treatment of diabetes.

Results: Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8).

Conclusion: Olanzapine is associated with a clinically important and significant increased risk of diabetes.

PubMed Disclaimer

Comment in

References

    1. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46:1396–1408. - PubMed
    1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696. - PubMed
    1. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778–783. - PubMed
    1. Meyer JM. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine- and risperidone-treated inpatients. Biol Psychiatry. 2001;49(8):536.
    1. Coulter DM, Bate A, Meyboom RHB, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ. 2001;322:1207–1209. - PMC - PubMed

Publication types